Hospital Superbug Shows Resistance to Last-Resort Antibiotic A critical antibiotic once relied upon as a final defense in hospitals is losing effectiveness against a persistent hospital-acquired bacterium,... on 27 July 2026 at 10h31
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division Lumara Bio brings together ITM's existing pipeline of early- and late-stage radiopharmaceutical therapies, including lead drug candidate... on 27 July 2026 at 10h29
Prepayments (CK93) – Nykredit Realkredit A/S To the Nasdaq Copenhagen 27.07.2026 Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby... on 27 July 2026 at 9h28
How to Delay Ovarian Aging and Prolong Female Fertility Researchers are investigating new approaches to delay ovarian aging, aiming to extend female fertility. This promising avenue could offer hope... on 27 July 2026 at 8h29
Aktsiaselts Infortar Investor Webinar introducing the results of the Q2 2026 Infortar will organize a webinar for investors on 3 August 2026 at 12:00 (EET) in Estonian and at 14:00 (EET) in English to introduce the second... on 27 July 2026 at 8h27
Share repurchase programme: Transactions of week 30 2026 The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank... on 27 July 2026 at 7h26
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology... on 27 July 2026 at 6h25